The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TECH | -18.22% | -6.37% | -1.31% | +11,312% |
| S&P | +19.61% | +98.99% | +14.75% | +1,570% |
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.
These two under-followed biotech stocks could be worth owning in your portfolio.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $316.96M | 3.5% |
| Gross Profit | $211.14M | 3.1% |
| Gross Margin | 66.61% | -0.3% |
| Market Cap | $8.07B | -28.6% |
| Market Cap / Employee | $2.60M | 0.0% |
| Employees | 3.1K | 0.0% |
| Net Income | -$17.70M | -143.6% |
| EBITDA | $101.96M | -21.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $162.19M | 6.8% |
| Accounts Receivable | $206.88M | -14.3% |
| Inventory | 189.4 | 5.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $429.96M | 5.7% |
| Short Term Debt | $14.10M | 9.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 2.73% | -3.3% |
| Return On Invested Capital | 10.43% | 0.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $93.31M | 62.2% |
| Operating Free Cash Flow | $98.20M | 30.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 85.19 | 73.21 | 71.47 | 113.45 | 65.40% |
| Price to Book | 6.11 | 5.35 | 4.45 | 4.00 | -28.68% |
| Price to Sales | 10.99 | 9.67 | 7.71 | 6.53 | -34.20% |
| Price to Tangible Book Value | 21.47 | 17.08 | 14.18 | 13.32 | -39.02% |
| Price to Free Cash Flow TTM | 66.18 | 56.81 | 54.78 | 38.66 | -37.63% |
| Enterprise Value to EBITDA | 165.38 | 144.96 | 84.16 | 80.94 | -11.34% |
| Free Cash Flow Yield | 1.5% | 1.8% | 1.8% | 2.6% | 60.34% |
| Return on Equity | 7.3% | 7.8% | 6.5% | 3.7% | -55.83% |
| Total Debt | $398.92M | $395.13M | $423.50M | $444.06M | 5.84% |
TECH earnings call for the period ending September 30, 2021.
TECH earnings call for the period ending June 30, 2021.
TECH earnings call for the period ending March 31, 2021.
TECH earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
